Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on precision oncology. The company uses the genetic principle of synthetic lethality to discover and develop cancer therapies, with news centered on its PRMT5 inhibitor program, including vopimetostat, and related oncology combination research.
Recurring updates also cover financial results and business highlights, clinical supply and collaboration activity, investor-conference participation, board and executive appointments, and equity compensation actions under the company’s 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Tango Therapeutics (Nasdaq:TNGX) priced an upsized underwritten public offering of 18,166,667 common shares and pre-funded warrants to purchase up to 1,833,395 shares at $30.00 per share and $29.999 per warrant.
Gross proceeds are expected to be about $600 million, with a 30-day option for underwriters to buy up to 3,000,009 additional shares. Closing is expected around June 11, 2026.
Tango Therapeutics (Nasdaq:TNGX) launched an underwritten public offering of $500 million in common stock. All shares are offered by the company, with a planned 30-day option for underwriters to purchase up to an additional $75 million in shares, subject to market conditions.
Tango Therapeutics (NASDAQ:TNGX) reported initial Phase 1/2 data for vopimetostat combinations in MTAP-deleted, RAS-mutant cancers. In second/third-line pancreatic ductal adenocarcinoma, vopimetostat plus daraxonrasib showed 92% ORR, 90% 6‑month PFS and 100% DCR, with 100% ORR in a small NSCLC cohort.
The vopimetostat plus zoldonrasib regimen in pancreatic cancer achieved 52% ORR, 74% 6‑month PFS and 96% DCR. Both combinations were generally well tolerated without related Grade 4/5 events. Tango plans a front-line Phase 3 pancreatic cancer trial and multiple additional data readouts in 2H 2026.
Tango Therapeutics (NASDAQ:TNGX) granted equity awards under its 2023 Inducement Plan, effective June 1, 2026, pursuant to Nasdaq Rule 5635(c)(4).
A new employee received a non-qualified option for 170,000 shares at an exercise price of $23.10 and 40,000 RSUs, with multi‑year vesting tied to continued employment.
Tango Therapeutics (NASDAQ:TNGX) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities totaled $379.8 million as of March 31, 2026, expected to fund operations into 2028.
Net loss was $45.5 million ($0.32/share). Vopimetostat combination trials, TNG456 and multiple 2026 data readouts are key upcoming milestones, alongside new senior leadership hires and board changes.
Tango Therapeutics (NASDAQ: TNGX) announced inducement equity awards effective May 1, 2026 under its 2023 Inducement Plan.
The Compensation Committee granted Mr. Matthew Gall a non‑qualified option for 240,000 shares and 40,000 RSUs, and a new employee an option for 199,650 shares and 33,250 RSUs, at an exercise price of $20.98 per share. Options have a 10‑year term; option vesting: 25% at year one then monthly over three years; RSUs vest in three approximately equal annual installments in May 2027–2029. Awards are subject to the 2023 Inducement Plan and award agreements.
Tango Therapeutics (NASDAQ: TNGX) announced leadership appointments to advance vopimetostat, a selective PRMT5 inhibitor, toward potential regulatory approval in pancreatic cancer. Appointments effective April 15 include Matthew Gall as CFO and Janice Kapty, PhD as SVP, with Yen-Ching Chua joining as Chief Development Operations Officer effective June 1.
The hires add finance, global clinical operations, and portfolio strategy expertise to support late-stage development and anticipated initial combination trial data with Revolution Medicines’ RAS(ON) inhibitors this year.
Tango Therapeutics (NASDAQ: TNGX) announced inducement equity grants effective February 2, 2026 under its 2023 Inducement Plan. The Compensation Committee granted a non-qualified option for 367,500 shares at an exercise price of $11.94 and 60,000 RSUs to a new employee.
Options vest 25% on February 2, 2027 then monthly over 36 months; RSUs vest in three tranches of 20,000 on or about February 1, 2027, February 14, 2028 and February 12, 2029, subject to continued employment.
Tango Therapeutics (NASDAQ: TNGX) reported Q4 and full‑year 2025 results and business highlights on March 5, 2026. Key points: $343.1 million cash as of Dec 31, 2025 with runway into 2028; vopimetostat pivotal 2L pancreatic study start expected in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026. The company announced a clinical supply agreement with Erasca, ongoing Revolution Medicines collaboration, and corporate leadership changes including a new CEO and Chief Regulatory Officer.
Tango Therapeutics (NASDAQ: TNGX) will report Q4 2025 financial results on March 5, 2026 before U.S. market open and will not host a conference call. Management will present at three investor conferences in early March 2026, with live webcasts available on the company’s Investors "Events & Presentations" page.
Replays will be archived on the website for 90 days following each presentation.